0001104659-23-123925.txt : 20231206 0001104659-23-123925.hdr.sgml : 20231206 20231206143541 ACCESSION NUMBER: 0001104659-23-123925 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231204 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231206 DATE AS OF CHANGE: 20231206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACURA PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000786947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 110853640 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10113 FILM NUMBER: 231469185 BUSINESS ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 CITY: PALATINE STATE: IL ZIP: 60067 BUSINESS PHONE: 847-705-7709 MAIL ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 STREET 2: . CITY: PALATINE STATE: IL ZIP: 60067 FORMER COMPANY: FORMER CONFORMED NAME: HALSEY DRUG CO INC/NEW DATE OF NAME CHANGE: 19920703 8-K 1 tm2332252d1_8k.htm FORM 8-K
false 0000786947 0000786947 2023-12-04 2023-12-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares









Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934


Date of Report (Date of earliest event reported): December 4, 2023




(Exact Name of Registrant as specified in its Charter)



New York 1-10113 11-0853640
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization)   Identification Number)


616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip code)



(Registrant’s telephone number, including area code)


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, $0.01 par value per share ACUR

OTC Market – OTC Expert Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 1.01 - Entry into a Material Definitive Agreement.


On December 4, 2023 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now totals $4,669,279, bears interest at 5.25% and matures on December 31, 2023, at which time all principal and interest is due (“Note”). Events of default under the Note include, among other items, bankruptcy events, failure to pay interest and principal when due and such failure continues for 5 days, and if Acura is generally not, or is unable to, or admits in writing its inability to, pay its debts as they become due. If any amount payable hereunder is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration, or otherwise, including upon an event of default, such overdue amount shall bear interest at the rate per annum of 7.5% from the date of such non-payment until such amount is paid in full.


The funding provided by AD Pharma will be used for operations through end of December 2023. There can be no assurance we will be successful in receiving additional financing. In the absence of the receipt of additional financing by the end of December 2023, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operation.


The inclusion of a description of the Note under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Note is a material agreement not made, or deemed not to be made, in the ordinary course of our business.


At November 1, 2023, AD Pharma directly owns approximately 66% of the outstanding common stock of the Company. The ownership percentage of the Company held by AD Pharma does not include their warrant to purchase 10.0 million shares of common stock of the Company. AD Pharma is an entity controlled by Mr. Schutte, of which Mr. Schutte is the managing partner and investor. At November 1, 2023, Mr. Schutte directly owns approximately 14% of the outstanding common stock of the Company.


Item 1.01 - Entry into a Material Definitive Agreement.


On December 4, 2023, Acura Pharmaceuticals, Inc. (“we” “Acura” or the “Company”), received the executed agreement to further amend the June 28, 2019 License, Development and Commercialization Agreement (“Agreement”) with Abuse Deterrent Pharma, LLC (“AD Pharma”), for the development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse.


The amendment to the Agreement extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 to March 31, 2024 (“NDA Acceptance Date”) (“Amended Agreement”).


AD Pharma may terminate the Amended Agreement at any time. Additionally, if the NDA for LTX-03 is not accepted by the FDA by the NDA Acceptance Date, AD Pharma may terminate the Amended Agreement and take ownership of the intellectual property rights of LTX-03 from the Company. Should AD Pharma choose not to exercise this option to terminate the Amended Agreement and the NDA for LTX-03 is subsequently accepted by the FDA, such option to terminate the Amended Agreement expires.


The inclusion of a description of the Amended Agreement with AD Pharma under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgment that the Amended Agreement is a material agreement not made, or deemed not to be made, in the ordinary course of our business.


Item 2.01 – Completion of Acquisition or Disposition of Assets


The contents of both Items 1.01 are incorporated herein by reference.


Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant


The contents of both Items 1.01 are incorporated herein by reference.





Acura Forward-Looking Statements


Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and these forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.


Forward-looking statements may include, but are not limited to:

  · whether the FDA will agree with or accept the results of our studies for our product candidates;
  · the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;
  · whether we can successfully submit a New Drug Application for LTX-03, request a priority review and whether such filings and requests will be accepted by the FDA;
  · our ability to obtain funding from Abuse Deterrent Pharma, LLC or other parties for our continuing operations, including the development of our products utilizing our LIMITx™ and Impede® technologies;
  · whether we can renegotiate the date by which we are required to obtain FDA acceptance, currently March 31, 2024, for an NDA for LTX-03 by our agreement with Abuse Deterrent Pharma, LLC on which we depend to finance operations;
  · whether we can renegotiate the date by which we are required to pay off the promissory notes and accrued interest to Abuse Deterrent Pharma, LLC, currently December 31, 2023;
  · whether our licensing partners will develop any additional products and utilize Acura for such development;
  · the expected results of clinical studies relating to LTX-03, a LIMITx hydrocodone bitartrate and acetaminophen combination product, or any successor product candidate, the date by which such studies will be complete and the results will be available and whether LTX-03 will ultimately receive FDA approval;
  · our business could be adversely affected by health epidemics in regions where third parties for which we rely, as in CROs or CMOs, have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely;
  · whether LIMITx will retard the release of opioid active ingredients as dose levels increase;
  · whether the extent to which products formulated with the LIMITx Technology reduce respiratory depression will be determined sufficient by the FDA to support approval or labelling describing safety features;
  · our and our licensee’s ability to successfully launch and commercialize our products and technologies;
  · the results and timing of our development of our LIMITx Technology, including, but not limited to, the submission of a NDA and/or FDA filing acceptance;
  · our or our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
  · the market acceptance of, timing of commercial launch and competitive environment for any of our products;
  · expectations regarding potential market share for our products;
  · our ability to develop and enter into additional license agreements for our product candidates using our technologies;
  · our exposure to product liability and other lawsuits in connection with the commercialization of our products;
  · the increasing cost of insurance and the availability of product liability insurance coverage;
  · the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
  · the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
  · the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
  · changes in regulatory requirements;
  · adverse safety findings relating to our commercialized products or product candidates in development;
  · whether the FDA will agree with our analysis of our clinical and laboratory studies;
  · whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our  technologies; and
  · whether our product candidates will ultimately perform as intended in commercial settings.





In some cases, you can identify forward-looking statements by terms such as “aim”, "anticipate", "believe", "could", "design", "estimate", "expect", "forecast", "goal", "guidance", "imply", “indicate”, "intend", "may", "objective", "opportunity", "outlook", "plan", "position", "potential", "predict", "project", "prospective", "pursue", "seek", "should", "strategy", "target", "would", "will", and other words of similar meaning, expressions, derivations of such words and the use of future dates intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in Acura’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and in other filings Acura makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date of the Current Report and are based on the Company’s current beliefs, assumptions, and expectations. While Acura may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking statements contained in this Current Report whether as a result of new information or future events, except as may be required by applicable law.


Item 9.01 - Financial Statements and Exhibits


Exhibit Number   Description
99.1   Amended Loan Schedule to Secured Promissory Note Dated November 10, 2022

Amendment #7 to License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC

104   Cover Page Interactive Data File (embedded within Inline XBRL document







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  By: /s/ Peter A. Clemens
    Peter A. Clemens
    Senior Vice President & Chief Financial Officer


Date: December 5, 2023



EX-99.1 2 tm2332252d1_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1


Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
  Date Principal Aggregated Principal
  Original Secured Promissory Note 11/10/2022 $2,319,279 $2,319,279
  Additional loans to be included:      
               Loan #1 12/22/2022 $250,000 $2,569,279
               Loan #2 1/19/2023 $250,000 $2,819,279
               Loan #3 2/22/2023 $250,000 $3,069,279
               Loan #4 3/20/2023 $250,000 $3,319,279
               Loan #5 5/19/2023 $150,000 $3,469,279
               Loan #6 7/10/2023 $200,000 $3,669,279
               Loan #7 7/28/2023 $250,000 $3,919,279
               Loan #8 8/30/2023 $250,000 $4,169,279
               Loan #9 10/11/2023 $250,000 $4,419,279
               Loan #10 12/04/2023 $250,000 $4,669,279






By: /s/ Peter A. Clemens

Peter A. Clemens

Senior Vice President & Chief Financial Officer


Date: December 4, 2023





EX-99.2 3 tm2332252d1_ex99-2.htm EXHIBIT 99.2


Exhibit 99.2





This AMENDMENT #7 (this "Amendment") TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the "Agreement") dated June 28, 2019 between Acura Pharmaceuticals, Inc. ("Acura"), a New York corporation, having a place of business at 616 N. North Court, Suite 120, Palatine, IL 60067, and Abuse Deterrent Pharma, LLC ("AD Pharma"), a Kentucky limited liability company, having a place of business at 333 E. Main Street, Suite 220, Louisville, Kentucky 40202, is made as of November 13, 2023.




WHEREAS, Acura and AD Pharma entered into that certain Amendment to the Agreement on October 16, 2020 ("Amendment #1");


WHEREAS, Acura and AD Pharma entered into that certain Amendment #2 to the Agreement on June 17, 2021 ("Amendment #2"); and


WHEREAS, Acura and AD Pharma entered into that certain Amendment #3 to the Agreement on February 28, 2022 ("Amendment #3") and


WHEREAS, Acura and AD Pharma entered into that certain Amendment #4 to the Agreement on November 10, 2022 ("Amendment #4" and


WHEREAS, Acura and AD Pharma entered into that certain Amendment #5 to the Agreement on December 8, 2022 ("Amendment #5" and


WHEREAS, Acura and AD Pharma entered into that certain Amendment #6 to the Agreement on June 15, 2023 ("Amendment #6" and together with Amendment #1, Amendment #2, Amendment #3, Amendment #4 and Amendment #5 constitute the "Prior Amendments"); and


WHEREAS, the Parties desire to amend the Agreement to provide for an extension to the LIMITx™ Regulatory Submission Timeline.


NOW THEREFORE, in consideration of the mutual covenants and promises contained in the Agreement, as amended, and this Amendment and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Acura and AD Pharma agree as follows:





1.1         Item 3 of Schedule 1 "LIMITx™ Regulatory Application Submission Timeline" is hereby amended and replaced in its entirety as follows:


3. By March 31, 2024, Acura must gain filing acceptance by the FDA of a Regulatory Approval Application for the Product.





2.1         Governing Law. This Amendment shall be governed by the laws of the State of New York without regard to its conflict of laws rules or principles.





2.2         Amendments. Except as expressly amended by this Amendment #7 and the "Prior Amendments", the Agreement shall remain unmodified and in full force and effect.


2.3         Entire Agreement. The Agreement (including the Schedules attached thereto), as amended by the "Prior Amendments" and this Amendment, constitutes the entire agreement of the Parties with respect to the subject matter hereof and supersede all prior understandings and writings between the Parties relating thereto.


2.4         Interpretation. Any capitalized terms used in this Amendment and not otherwise defined herein shall have the meaning provided in the Agreement.


2.5         Counterparts. This Amendment may be executed manually or electronically by the Parties, in any number of counterparts, each of which shall be considered one and the same amendment and shall become effective when a counterpart hereof shall have been signed by each of the Parties and delivered to the other Party.


IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed in their names by their properly and duly authorized officers or representatives as of the date first written above.





By: /s/ Peter A. Clemens

Name: Peter A. Clemens

Title: CFO and Vice President






By: /s/ John Schutte

Name: John Schutte

Title: Managing Partner



EX-101.SCH 4 acur-20231204.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 acur-20231204_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 acur-20231204_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Dec. 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 04, 2023
Entity File Number 1-10113
Entity Central Index Key 0000786947
Entity Tax Identification Number 11-0853640
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 616 N. North Court
Entity Address, Address Line Two Suite 120
Entity Address, City or Town Palatine
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60067
City Area Code 847
Local Phone Number 705-7709
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ACUR
Entity Emerging Growth Company false
XML 8 tm2332252d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000786947 2023-12-04 2023-12-04 iso4217:USD shares iso4217:USD shares false 0000786947 8-K 2023-12-04 ACURA PHARMACEUTICALS, INC. NY 1-10113 11-0853640 616 N. North Court Suite 120 Palatine IL 60067 847 705-7709 Common Stock, $0.01 par value per share ACUR false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '1TAE<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !T=(978IFI9.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OIW^P8.CFLN))07!!\18FL[O!I@W)2+MO;UIWNX@^@,?,_/+- M-S M>HE#H.

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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://acurapharm.com/role/Cover Cover Cover 1 false false All Reports Book All Reports acur-20231204.xsd acur-20231204_lab.xml acur-20231204_pre.xml tm2332252d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2332252d1_8k.htm": { "nsprefix": "acur", "nsuri": "http://acurapharm.com/20231204", "dts": { "schema": { "local": [ "acur-20231204.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "acur-20231204_lab.xml" ] }, "presentationLink": { "local": [ "acur-20231204_pre.xml" ] }, "inline": { "local": [ "tm2332252d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://acurapharm.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332252d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332252d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://acurapharm.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-123925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-123925-xbrl.zip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end